When putting together your watch list, look for stocks with an 80 or higher RS Rating. Vertex Pharmaceuticals stock now meets that criteria, with a jump from 75 to 84 Wednesday.
As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.
IBD's unique rating tracks share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the best stocks typically have an 80 or higher RS Rating as they launch their biggest climbs.
Looking For Winning Stocks? Try This Simple Routine
Is Vertex Pharmaceuticals Stock A Buy?
The IBD Big Cap 20 stock is trying to complete a flat base with a 324.85 buy point. See if the stock can break out in volume at least 40% higher than normal.
The biotech company reported 14% earnings growth last quarter. Revenue increased 18%. Keep an eye out for the company's next round of numbers on or around Feb. 1.
Vertex Pharmaceuticals stock holds the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
